What question did this study set out to answer?

To explore the effects of prostacyclin and dipyridamole on platelet retention and hyperaggregability in atherosclerosis patients.

March 1, 1986Angiology

Platelet Hyperaggregability, Blood Prostacyclin and Dipyridamole

View Full Paper

Ask AI

Bookmark

Why the study?

Does dipyridamole improve platelet hyperaggregability and prostacyclin levels in atherosclerosis patients?

Population

Atherosclerosis patients

Design

Other

Authors

HSH Solvay MKM. Kahn MCM CloarecInserm

Discussion

Member takes

Implication

450 mg dipyridamole may maximize erythrocyte prostacyclin loading in atherosclerosis; leaves open management of the 10% with persistent hyperaggregability.

Key Points

To explore the effects of prostacyclin and dipyridamole on platelet retention and hyperaggregability in atherosclerosis patients.
Investigated blood levels of prostacyclin and platelet retention tests in patients with atherosclerosis.
Administered varying doses of dipyridamole, particularly measuring effects at 450 mg daily.
About 10% of treated atherosclerosis patients still experience platelet hyperaggregability despite dipyridamole.
Erythrocyte ATP reserves influence prostacyclin presence on erythrocyte sites.
Platelet retention tests improved with increasing daily doses of dipyridamole, peaking at 450 mg.

Structured PICO

Does dipyridamole improve platelet hyperaggregability and prostacyclin levels in atherosclerosis patients?

Population

Atherosclerosis patients

Intervention

Dipyridamole (up to 450 mg daily)

Outcome

Platelet hyperaggregability and prostacyclin levelssurrogate

Dipyridamole increases erythrocyte prostacyclin load in a dose-dependent manner up to 450 mg daily, though a subset of atherosclerosis patients exhibit resistance.

Cite This Study

Solvay et al. (1986) studied this question.

synapsesocial.com/papers/6a7659f359ee065f408144f2 https://doi.org/10.1177/000331978603700306

View Full Paper

Ask AI

Bookmark

Implication

450 mg dipyridamole may maximize erythrocyte prostacyclin loading in atherosclerosis; leaves open management of the 10% with persistent hyperaggregability.

Platelet Hyperaggregability, Blood Prostacyclin and Dipyridamole

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Platelet Hyperaggregability, Blood Prostacyclin and Dipyridamole

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider